



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number: **0 555 478 A1**

⑫

EUROPEAN PATENT APPLICATION
published in accordance with Art.
158(3) EPC

⑲ Application number: **91915722.2**

⑤① Int. Cl.⁵: **C07D 239/34, C07D 239/42,
C07D 453/02, A61K 31/505**

⑳ Date of filing: **29.08.91**

⑥⑥ International application number:
PCT/JP91/01152

⑥⑦ International publication number:
WO 92/04333 (19.03.92 92/07)

③① Priority: **31.08.90 JP 231029/90**
29.05.91 JP 155628/91

④③ Date of publication of application:
18.08.93 Bulletin 93/33

⑥④ Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

⑦① Applicant: **NIPPON SHINYAKU COMPANY,
LIMITED**
14, Kisshoin Nishinosho Monguchicho
Minami-ku Kyoto-shi Kyoto 601(JP)


⑦② Inventor: **CHOKAI, Shoichi**
16-6, Shinocho Miharu 2-chome
Kameoka-shi; Kyoto 621(JP)
Inventor: **AOKI, Tomiyoshi**
705-102, Harimadacho
Moriyama-shi, Shiga 524(JP)
Inventor: **KIMURA, Kiyoshi**
55-21, Ankojicho 5-chome
Takatsuki-shi, Osaka 569(JP)

⑦④ Representative: **Vogeser, Werner, Dipl.-Ing. et
al**
Patent- und Rechtsanwälte, Hansmann
Vogeser Dr. Boecker Alber Dr. Strych,
Albert-Rosshaupter-Strasse 65
D-81369 München (DE)

⑤④ **PYRIMIDINE DERIVATIVE AND MEDICINE.**

⑤⑦ The invention aims at obtaining a novel compound which is excellent in central nervous system selectivity and reduced in side effects and has an activity of improving the function of learning and memory, thus providing an excellent medicine for dementia. The invention relates to a compound represented by general formula (I), a pharmacologically acceptable salt thereof, and an agent for remedying the disturbance of learning and memory containing the same as the active ingredient of formula (I), wherein R¹ and R² may be the same or different from each other and each represents hydrogen, hydroxy, alkoxy, trifluoromethyl or halogen; A represents methyl, trifluoromethyl or tertbutyl; and Y represents O or NH.

EP 0 555 478 A1




TECHNICAL FIELD

This invention relates to pyrimidine derivatives and their pharmacologically acceptable salts represented by the following general formula [I].

5


10



15 wherein A and B are as follows:

When A represents

20



25 B represents methyl, trifluoromethyl, or tert-butyl;

When B represents

30



35 A represents methyl, trifluoromethyl, or tert-butyl.

R¹ and R² are the same or different and each is a hydrogen atom, a hydroxy group, an alkoxy group, trifluoromethyl or halogen.

R³ represents (1), (2) or (3), represented by the following formulas.

40

(1)




45

wherein Y represents O or NH.

50

(2)




55

wherein R⁴ and R⁵ represent the following ① or ②.

①. R⁴ and R⁵ are the same or different and each is hydrogen or alkyl group.

②. R⁴ and R⁵ link to form piperazino which is substituted with an aryl group or an aralkyl group.



wherein Y represents O or NH. m is 2 or 3. R⁶ and R⁷ are the same or different and each is a hydrogen atom or an alkyl group, or form a 5 to 6 membered cyclic-amino group with the adjacent nitrogen atom.

These cyclic-amino groups may include another nitrogen, oxygen or sulfur atom, and moreover, those may be substituted with an aryl group with or without substituent(s), an aralkyl group with or without substituent(s), or an aroyl group with or without substituent(s).

Since the compounds of the present invention have improving effect on learning and memory disorders with low toxicity as described later, those are useful as remedies for dementia etc.

BACKGROUND ART

According with the aging of the population, dementia have been a dominant disease in the medication of the elderly patients. However, the remedies for the treatment of dementia have not been established. Cerebral metabolism enhancers, cerebral blood flow improving agents, tranquilizers, cholinomimetic agents and the like have been tried to use for the treatment. However, the effect of these agents are not reproducible and insufficient. Therefore, better remedies for treatment have been required.

In the dementia of alzheimer type, a type of senile dementia, various nervous systems are damaged. Especially, it has been reported that cholinergic nervous systems, which play important roles in learning and memory functions, are significantly damaged. Therefore, the development of central acetylcholinergic neuron enhancers have been an large stream of development in the improving agents for learning and memory disorders. As for the acetylcholinergic neuron enhancers, precursors (such as choline and lecithin), choline esterase inhibitors or muscarinic agonists have been developed so far. However, they are not satisfactory enough.

On the other hand, various kinds of pyrimidine derivatives have been reported.(for example, CA 93:45871w, 97: 158036d, 98:34562y, 100:209733u, 101:110856v, 102:162193s, 104:47176t, 107:236641p, 109:92924z and so forth). It is described in CA 100:209733u that the phleomycin amplifying effect of the compounds which have similar structures to the compounds of the present invention. Also in CA 104:47176t, it is described that the plant's growth regulating effect of the compounds which have similar structures to the compounds of the present invention.

However, up to this point, there have been no literatures describing that the compounds of the present invention and analogous pyrimidine derivatives have improving effects on learning and memory disorders.

DISCLOSURE OF THE INVENTION


The inventors have studied in order to obtain the compounds which are superior to the conventionally known drugs for learning and memory disorders in point of effectiveness, safety and durability.

Accordingly, the object of the present invention has been to obtain new compounds which have improving effect on learning and memory disorders with good selectivity in central nervous system and little side effects and then to provide a good medicine for the treatment of dementia.


The gist of the present invention is in the chemical structure of the compound itself which is represented by a general formula [I]. These are not only new compounds which are not yet described in any literatures so far, but also showing good pharmacological effects with low toxicity as described later. However, the following compounds such as (i) to (x), as described above, are known compounds which are already reported in literatures.

However, in also these compounds, their excellent improving effects on learning and memory disorder have been found for the first time by the inventors. Therefore, these compounds are also included in the present invention as the improving agents for learning and memory disorders.


(i) The compound wherein A is phenyl, B is methyl and R³ is




(ii) The compound wherein A is phenyl, B is methyl and R³ is




(iii) The compound wherein A is methyl, B is phenyl and R³ is



(iv) The compound wherein A is methyl, B is phenyl and R³ is



(v) The compound wherein A is methyl, B is phenyl and R³ is



(vi) The compound wherein A is methyl, B is phenyl and R³ is -NH₂.

(vii) The compound wherein A is methyl, B is 4-chlorophenyl and R³ is -NH₂.

(viii) The compound wherein A is methyl, B is 4-methoxyphenyl and R³ is -NH₂.

(ix) The compound wherein A is phenyl, B is methyl and R³ is -NH₂.

(x) The compound wherein A is 4-chlorophenyl, B is methyl and R³ is -NH₂.

In the general formula [I], as the alkoxy group represented by R¹ and R², it is preferable to be straight or branched chain having 1 to 4 carbon atoms and illustrative of such alkoxys are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or sec-butoxy and so forth. The examples of the halogens are chlorine, fluorine, bromine, iodine and the like.

As the alkyl groups represented by R⁴ and R⁵, it is preferable to be straight or branched chain having 1 to 4 carbon atoms. And examples of the alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and the like.

As the aryl group which is a substituent of piperazino moiety represented by -NR⁴R⁵, it is preferable to be ones having 6 to 12 carbon atoms. And examples of the aryl are phenyl, α-naphthyl, β-naphthyl, biphenyl and so on, which is un-substituted or substituted with alkoxy group.

As the aralkyl groups, it is preferable to be ones having 7 to 14 carbon atoms. And examples of the aralkyl are benzyl, phenetyl, 3-phenylpropyl, naphthylmethyl, diphenylmethyl and so on, which is un-substituted or substituted with halogen(s).

As the alkyl groups represented by R⁶ and R⁷, it is preferable to be ones described above.

As the 5 to 6 membered cyclic amino groups represented by $-NR^6R^7$, it is preferable to be ones such as pyrrolidino, piperidino, piperazino, morpholino and thiomorpholino. As the aryl or aralkyl groups as the substituent group of the cyclic amino moiety, it is preferable to be ones described above.

As the aroyl group, benzoyl un-substituted or substituted with alkoxy(ies) or halogen(s) is preferable.

Any reference to the compounds of the present invention, in addition to the examples of compounds related to the process for production described later, there may be also mentioned the following examples of compounds.

4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-6-methyl-2-phenylpyrimidine

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-phenyl-6-trifluoromethylpyrimidine

4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-2-phenyl-6-trifluoromethylpyrimidine

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-(4-fluorophenyl)-6-trifluoromethylpyrimidine

4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-2-(4-fluorophenyl)-6-trifluoromethylpyrimidine

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-(4-trifluoromethylphenyl)-6-trifluoromethylpyrimidine

4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-2-(4-trifluoromethylphenyl)-6-trifluoromethylpyrimidine

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-phenyl-6-trifluoromethylpyrimidine

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-tert-butyl-2-(4-trifluoromethylphenyl)pyrimidine


4-(1-azabicyclo[2,2,2]octo-3-ylamino)-2-(4-methoxyphenyl)-6-methylpyrimidine

4-(1-azabicyclo[2,2,2]octo-3-ylamino)-2-(4-fluorophenyl)-6-methylpyrimidine


4-(1-azabicyclo[2,2,2]octo-3-ylamino)-2-(4-trifluoromethylphenyl)-6-methylpyrimidine

The compounds of the present invention can be produced, for example, by the following methods.


Method A: When R^3 is $-NR^4R^5$, $-NH-(CH_2)_mNR^6R^7$ or



(III)



(IV)



(Ia)


(Wherein, A and B are the same as the defined above, X is halogen. $HNR^{11}R^{12}$ represents HNR^4R^5 , $H_2N(CH_2)_mNR^6R^7$ or



$R^4 - R^7$ and m are the same as the defined above.)


Method B: When R^3 is $-O-(CH_2)_mNR^6R^7$ or





(wherein, A, B, X, R⁶, R⁷ and m are the same as the defined above.)

Method C: When R³ is -O-(CH₂)_mNR⁶R⁷ or



(wherein A, B, X, R⁶, R⁷ and m are the same as the defined above.)

40 Method A

[Ia] can be produced by the reaction of halogenopyrimidine [III] with amine [IV] in an inert solvent, in the presence of a base at 30 to 120 °C, preferably 60 to 80 °C.

45 As the reaction solvents, an aprotic polar solvent such as acetonitrile, dimethylsulfoxide, and N,N-dimethylformamide (DMF), alcohols such as methanol, ethanol and isopropanol, ethers such as tetrahydrofuran, dimethoxyethane, diethylether and dioxane, glimes such as methylcellosolve and ethyleneglycol dimethylether, halogenated hydrocarbons such as methylene chloride and chloroform, hydrocarbons such as benzene, toluene and xylene, or the mixture of these solvents can be used.

50 As the bases, alkali carbonates (for example, potassium carbonate, sodium carbonate etc.), alkali bicarbonates (for example, potassium bicarbonate, sodium bicarbonate etc.), inorganic salts of alkali hydroxides (for example, potassium hydroxide, sodium hydroxide etc.) or excess amines (HNR¹¹R¹²) can be used.

The reaction time is usually 4 to 24 hours, although it may vary depending on the kind of starting materials, bases and solvents used.

55 The amount of amine [IV] is preferably 1 to 1.2 moles per 1 mole of [III].

Method B

Either [Ib] or [Ic] can be produced by the reaction of halogenopyrimidine [III] with hydroxyalkylamine [V] or quinuclidol [V'] in an inert reaction solvent, in the presence of a catalyst at 0 to 80 °C, preferably 10 to 30 °C.

As the reaction solvents, N,N-dimethylformamide (DMF) or ethers such as tetrahydrofuran, dimethoxyethane, diethylether, dioxane, diethyleneglycol and dimethylether, or the mixture of these solvents can be used. As the catalysts, sodium hydride, sodium amide, potassium-tert-butoxide, butyllithium and the like can be used.

The reaction time is usually 2 to 24 hours although it may vary depending on the kind of starting materials, solvents and catalysts used.

The amount of hydroxyalkylamine [V] or quinuclidol [V'] is preferably 1 to 1.2 moles per 1 mole of [III].

Method C


[I] can be produced by the reaction of hydroxypyrimidine [VI] with halogenoalkylamine [VII] or halogenoquinuclidine [VII'] in a solvent which is mentioned in method A, in the presence of a base at 0 to 80 °C.

As the bases, sodium hydride, potassium carbonate, sodium hydroxide, potassium hydroxide and the like can be used.

The reaction time is usually 2 to 10 hours although it may vary depending on the kind of starting materials, bases and solvents used.

The amount of halogenoalkylamine [VII] or halogenoquinuclidine [VII'] is preferably 1 to 1.2 moles per 1 mole [VI].

The starting materials of [III] and [IV], which are described in detail as the reference examples, can be produced as follows.



(wherein A, B and X are the same as defined above. R is a lower alkyl.)

[VI] can be produced by the reaction of amidine [VIII] with acylacetic acid ester [IX] in the presence of a base (inorganic salts such as potassium carbonate and sodium carbonate, or organic salts such as triethylamine), in an inert solvent (for example, alcohols such as methanol and ethanol, aprotic solvents such as acetonitrile and N,N-dimethylformamide.) at 60 to 140 °C for 5 to 24 hours. In addition, [III] can be prepared by heat-refluxing this with phosphorus oxychloride for 10 minutes to 1 hour.

Although there are some compounds in the present invention which possess asymmetric carbons, both optical isomers of each compound and their racemic mixtures are included in the present invention. The optical isomers can be obtained by optically resolution of their racemic mixtures based upon their basicity with the use of optical active acids (such as tartaric acid, dibenzoyltartaric acid, mandelic acid, 10-camphor-sulfonic acid) according to conventional methods, or by using optically active compounds, [IV], [V] and [VII'] prepared previously as raw materials.

The desired compound [I] produced by this manner can be isolated and purified in the form of free base or acid additional salt, for example, by concentration, change of liquid property, transference of solute, solvent extraction, crystallization, fractional distillation, chromatography etc. according to the known method per se.

The acid additional salts can include the salts of mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid, and the salts of organic acids such as acetic acid, oxalic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, p-toluenesulfonic acid, benzenesulfonic acid and methanesulfonic acid.

5 When the compounds of the present invention are given as medicines, those are administered to animals including human, as it is or as pharmaceutical compositions which contains the compounds for the concentration of, for example, 0.1 to 99.5 %, preferably 0.5 to 90 % in pharmaceutically acceptable carriers which are nontoxic and inert.

As the carriers, more than one kind of diluents, filling materials and other supplementary substances for
10 prescription in the forms of solid, semi-solid or liquid states are used. It is preferable that pharmaceutical compositions are administered as a unit dosage form. The pharmaceutical compositions of the present invention can be administered orally, intra-tissue, locally (such as percutaneous administration etc.) or per rectum. It is the matter of course that those should be administered in suitable form depending on the way of administration.

15 Although it is preferable that the doses as the improving agents for learning and memory disorders should be controlled considering the patient's condition such as age and body weight and so on, administration route, and disposition and degree of the diseases etc., it is general ranges that one-day dose of the effective constituent in the present invention for adults is usually 0.1mg to 1g/human, preferably 1 to 300mg/human. Depending on the cases, sometimes the dose below the above dose range is enough, or
20 contrary, some requires more dose than the range. It is also preferable to administer in divided doses by 2 to 4 times a day.

Oral administration can be carried out using solid or liquid unit dosage such as fine powder, powder formulations, tablets, sugar-coating drugs, capsules, granules, suspensions, liquid preparations, syrups, drops, sublingual tablets and other formulations.

25 Fine powders are produced by pulverizing the active substances to be adequately fine. Powder formulation are prepared by pulverizing the active substances to be adequately fine and admixing with similarly pulverized pharmaceutical carriers, for example, edible carbohydrates such as starch or mannitol, and the others. If necessary, it may be admixed with flavoring agents, preservatives, dispersing agents, coloring agents, perfume and the others.

30 Capsules are produced by filling fine powders or powder formulation which are previously pulverized as the mentioned above, or granulated substances as mentioned in the section of tablets, into capsule integuments such as gelatin capsule. The pulverized substances are admixed with lubricants or fluidifying agents such as colloidal silica, talc, magnesium stearate and potassium stearate as well as solid polyethyleneglycol, and then the filling procedure can be carried out. The effectiveness of drugs when the capsule is taken can be improved, if disintegrators or solubilizing agents such as carboxymethylcellulose,
35 calcium carboxymethyl cellulose, lower substituted hydroxypropyl cellulose, sodium croscarmellose, sodium carboxymethyl starch, calcium carbonate and sodium carbonate are added into the powder.

Moreover, soft capsule can be prepared by suspending and dispersing the fine powder of this product in vegetable oil, polyethyleneglycol, glycerin or surfactants and then wrapping this with gelatin sheets.

40 Tablets can be produced the way that powdery mixtures is prepared by adding filler, then it is granulated or slugged, and then compressed after addition of disintegrator or lubricant. The powder mixtures are prepared by admixing the suitably pulverized substance with the above mentioned diluents and bases, and if necessary, binders (for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, gelatin, polyvinylpyrrolidone, polyvinylalcohol and the like), reabsorbing agents (for example, quaternary salts) and adsorbing agents (for example, bentonite, kaolin, dicalcium phosphate and the like) may be used simultaneously in this procedure. The powdery mixture can be changed to granule by the way that first it is moistened with binders, for example, syrup, starch paste, acacia, cellulose solution or high polymer solution, and then it is stirred to mix, dried and pulverized. In stead of granulating the powder in this way, it is possible to make granule by pulverizing the incomplete form of slug which is obtained after the previous
50 compression by the compressor.

The granule made by this way can be prevented from mutual adhering by adding lubricants such as stearic acid, stearate, talk and mineral oil. The mixture lubricated in this way is subsequently compressed. The bare tablets made in this manner can be given film-coating or sugar-coating.

55 The drugs may be directly compressed after mixing with fluid inactive carrier without the process of granulation and slugging. The transparent or semitransparent protecting film which is consisted of sealing-up film made from shellac, the film made from sugar and high polymer, and the things like rubbing-up film consisted of wax can also be used.

Other oral dosage formulation such as solutions, syrups and elixirs can be also made as unit dosage form which contain a constant dose of drug in a constant amounts of the formulation. Syrups are produced by dissolving compounds in suitable perfumed water and elixirs are produced by using nontoxic alcohol carriers. Suspensions is prescribed by dispersing a compound in nontoxic carriers. It is also possible to add solubilizing agents or emulsifying agents (for example, ethoxylated-isostearylalcohols or polyoxyethylenesorbitol esters), preservatives, flavoring agents (for example, peppermint oil or saccharin) and the others, when required.

If necessary, the prescription of unit dosage for oral administration may be as microcapsulated formulation. The said prescription can also provide prolongation of action time and lasting release of drugs by film-coating and filling up into high polymer wax and the like.

Intra-tissue administrations can be carried out using liquid unit dosage form, such as the form of solution and suspension which are prepared for subcutaneous, intramuscular or intravenous injections. These formulations are produced by the way that a certain amount of compound is suspended or dissolved in nontoxic liquid carriers such as aqueous or oily vehicles which are suitable for the purpose of injection, and then the said suspension or solution is sterilized. Nontoxic salts or the salt-solution may be added to them in order to isotinize the injections. In addition, stabilizers, preservatives, emulsifiers and the like can be used at the same time with them.

Rectal administration can be carried out using suppositories and the likes which are produced by dissolving or suspending compounds in water-soluble or insoluble solids with low melting point, for example, polyethyleneglycol, cacao butter, semisynthetic fats and oils (such as witepsol, a registered trademark), higher esters (such as myristilpalmitate) and their mixture.

THE BEST MODE FOR PRACTICING THE INVENTION

The present invention will be further illustrated by giving reference examples, examples, test examples and pharmaceutical examples of the compound of the present invention hereinafter.

Reference Example 1

(1) Preparation of 4-methoxybenzimidic acid methylester hydrochloride

25 g of anisonitril was dissolved in 250 ml of methanol. After saturation with hydrogen chloride gas under cooling in ice-water and stirring, the solution was stirred at room temperature for 15 hours. Then, methanol was evaporated in vacuo. Ether was added to the residue and the crystals were filtered off and dried. Whereby 35.9 g of the desired substance was obtained as white crystals. Melting point is 111 to 112 °C (Decomposition).

(2) Preparation of 4-methoxybenzamidine hydrochloride

35.9 g of 4-methoxybenzimidic acid methylester hydrochloride was dissolved in 300 ml of methanol. After saturation with ammonia gas under cooling in ice-water and stirring, the solution was stirred at room temperature for 15 hours. Then, methanol was evaporated in vacuo. Ethyl acetate was added to the residue. The precipitated crystals were filtered off and dried. Whereby 30.9 g of the desired substance was obtained as white crystals. Melting point is 220 to 221 °C.

(3) Preparation of 4-hydroxy-2-(4-methoxyphenyl)-6-methylpyrimidine

To the mixture of 10 g of 4-methoxybenzamidine hydrochloride, 7.7 g of ethyl acetoacetate and 16.3 g of potassium carbonate were added 120 ml of ethanol, and the mixture was heat-refluxed with stirring for 7 hours. The reaction mixture was cooled and filtered to remove insoluble substances. The filtrate was evaporated. Water was added to the residue to dissolve and then the resulting solution was neutralized with acetic acid. The precipitated crystals were filtered off, washed with water and dried. Whereby 10.9 g of the desired substance was obtained as white crystals. Melting point is 202 to 203 °C.

In the same way, the following compounds were obtained.

2-(4-fluorophenyl)-4-hydroxy-6-methylpyrimidine. Melting point is 224 to 225.5 °C.

4-hydroxy-2-(4-methoxyphenyl)-6-trifluoromethylpyrimidine. Melting point is 239 to 240.5 °C.

4-hydroxy-6-methyl-2-(4-trifluoromethylphenyl)pyrimidine. Melting point is 222 to 224 °C.

Reference Example 2

Preparation of 4-chloro-2-(4-methoxyphenyl)-6-methylpyrimidine

6.5 g of 4-hydroxy-2-(4-methoxyphenyl)-6-methylpyrimidine prepared in reference example 1 (3) was added to 30 ml of phosphorus oxychloride, and the mixture was refluxed with stirring for 30 minutes. The reaction mixture was cooled and poured into diluted ammonia solution and the precipitated crystals were filtered off. The crystals were dissolved in chloroform. After the chloroform layer was washed twice with water, it was dried with anhydrous magnesium sulfate and was evaporated in vacuo. The residue was crystallized with n-hexane and filtered off. Whereby 5.1 g of crystals was obtained. Melting point is 80 to 81 °C.

In the same way, the following compounds were obtained.

4-chloro-2-(4-fluorophenyl)-6-methylpyrimidine. Melting point is 87 to 88.5 °C.

4-chloro-2-(4-methoxyphenyl)-6-trifluoromethylpyrimidine. Melting point is 54 to 56 °C.

4-chloro-6-methyl-2-(4-trifluoromethylphenyl)pyrimidine. Melting point is 66 to 67 °C.

Reference Example 3

Preparation of 4-hydroxy-6-(4-methoxyphenyl)-2-methylpyrimidine

1.89 g of acetamidine hydrochloride and 4.44 g of ethyl paramethoxybenzoylacetate were dissolved in 40 ml of ethanol.

After addition of 5.52 g of potassium carbonate, the solution was refluxed with stirring for 8 hours, and then evaporated in vacuo. 5 g of sodium hydroxide was dissolved in 30 ml of water and this was added to the evaporated residue. Add ether, then extract, the aqueous layer was neutralized with acetic acid. The resulting precipitations were filtered off, washed with water and dried. Then 1.1 g of crystals were obtained. Melting point is 270 to 272 °C.

Reference Example 4

Preparation of 4-chloro-6-(4-methoxyphenyl)-6-methylpyrimidine

9 g of 4-hydroxy-6-(4-methoxyphenyl)-2-methylpyrimidine was added to 60 ml of phosphorus oxychloride and the mixture was refluxed with stirring for 30 minutes. The reaction mixture was added to diluted ammonia solution little by little, and the precipitate was filtered. This was dissolved in chloroform and washed with potassium carbonate solution. After washing, the chloroform layer was dried with anhydrous magnesium sulfate and evaporated in vacuo. The residue was crystallized with n-hexane and filtered off. Whereby 5.78 g of the crystals were obtained. Melting point is 65 to 67 °C.

Example 1

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-methoxyphenyl)-6-methylpyrimidine maleate

15.0 g of 4-chloro-2-(4-methoxyphenyl)-6-methylpyrimidine and 8.13 g of 3-quinuclidinol were dissolved in 150 ml of N,N-dimethylformamide.

Then 2.56 g of 60 % sodium hydride was added to the solution under ice-cooling and stirring. After stirring for 2 hours under ice-cooling and additionally for 5 hours at room temperature, the reaction mixture was poured into ice-water and the oily substance was extracted with ethyl acetate. After the ethyl acetate layer was washed twice with water, it was dried with anhydrous magnesium sulfate and evaporated in vacuo. The residue was applied to a column chromatography with silica gel (Wako gel C-200 500g, elution with chloroform and 3 % methanol-chloroform in order), then 16.9 g of oily substance was obtained. This was dissolved in 100 ml of methanol, methanol solution of 6.0 g of maleic acid was added.

After stirring, the solution was evaporated in vacuo. Ether was added to the residue to crystallize then the crystals were filtered off. Whereby 16.4 g of the crystals were obtained. These were recrystallised with ethanol, whereby 12.6 g of the crystals were obtained. Melting point is 163 to 164 °C.

Elementary analysis for (C ₁₉ H ₂₃ N ₃ O ₂ • C ₄ H ₄ O ₄ 441.48)			
Calculated (%)	C:62.57	H:6.16	N:9.52
Found (%)	C:62.51	H:6.40	N:9.61

Example 2

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-methoxyphenyl)-6-methylpyrimidine maleate

1 g of 4-chloro-2-(4-methoxyphenyl)-6-methylpyrimidine was dissolved in tetrahydrofuran 15 ml and DMF 10 ml. After addition of 542 mg of (R)-(+)-3-quinuclidinol thereto, 340 mg of 60 % sodium hydride was added to the solution under ice-cooling and stirring. After stirring for 2 hours under ice-cooling and additionally for 17 hours at room temperature, the reaction mixture was poured into ice-water and extracted with ethyl acetate. After the ethyl acetate layer was extracted with diluted hydrochloride solution, the aqueous layer was neutralized with an aqueous sodium hydroxide solution. Then this was extracted with ethyl acetate. After washing the ethyl acetate layer with water and drying with anhydrous magnesium sulfate, the solvent was evaporated in vacuo. The resulting yellow crystals were purified with column chromatography with silica gel(Wako gel C-200 20 g, elution with chloroform and 3 % methanol-chloroform in order), then 590 mg of white crystals were obtained.

After the crystal was dissolved in methanol and added maleic acid 211mg/methanol 2ml, ether was added and the precipitated crystals was filtered off. This was recrystallized with acetonitrile/ether mixed solution. Whereby 624 mg of the desired compound was obtained as white crystal. Melting point is 158.5 to 159.5 °C.

Elementary analysis for(C ₁₉ H ₂₃ N ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:62.57	H:6.16	N:9.52
Found (%)	C:62.88	H:6.16	N:9.52

Specific rotation $[\alpha]_D$ (20 °C) = -33.2 (c = 1, H₂O)

Example 3

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-(4-methoxyphenyl)-6-methylpyrimidine

0.6 g of 4-chloro-2-(4-methoxyphenyl)-6-methylpyrimidine and 0.76 g of 1-diphenylmethyl-4-(2-hydroxyethyl)piperazine were dissolved in 20 ml of dried tetrahydrofuran. After addition of 0.1 g of 60 % sodium hydride, the mixture was stirred for 20 hours at room temperature. The reaction mixture was poured into ice-water and was extracted with ethyl acetate. After the extract was washed with water and was dried with anhydrous magnesium sulfate, then was evaporated in vacuo. The resulting residue was purified with column chromatography with silica gel (Wako gel C-200, elution with chloroform and then chloroform:ethyl acetate = 8:1). The desired fraction was crystallized by evaporating the solvent under reduced pressure. The crystals were recrystallized with the solvent mixed with chloroform and ether, resulting to obtain 0.6 g of crystals. Melting point is 132 to 133 °C.

Elementary analysis for(C ₃₁ H ₃₄ N ₄ O ₂)			
Calculated (%)	C:75.28	H:6.93	N:11.33
Found (%)	C:74.95	H:7.03	N:11.24

Example 4

4-(4-diphenylmethylpiperazino)-2-(4-methoxyphenyl)-6-methylpyrimidine

1.17 g of 4-chloro-2-(4-methoxyphenyl)-6-methylpyrimidine and 1.38 g of 1-diphenylmethylpiperazine were dissolved in 20 ml of N,N-dimethylformamide. After the addition of 1 g of potassium carbonate, the mixture was stirred for 6 hours at 80 to 85 °C. The reaction mixture was poured into ice-water, then the resulting crystals were filtered off, washed with water and dried. Whereby 2.2g of crystals were obtained. 1.85g of the crystals were obtained by recrystallizing with ethanol. Melting point is 147 to 149 °C.

Elementary analysis for (C ₂₉ H ₃₀ N ₄ O)			
Calculated (%)	C:77.30	H:6.71	N:12.43
Found (%)	C:77.46	H:6.89	N:12.24

Example 5

4-(4-methoxyphenyl)-2-methyl-6-(2-piperidinoethoxy)pyrimidine dihydrochloride

1.17 g of 4-chloro-6-(4-methoxyphenyl)-2-methylpyrimidine and 0.65 g of 2-piperidinoethanol were dissolved in 10 ml of dried tetrahydrofuran. After the addition of 60% sodium hydride 0.2g, the mixture was stirred for 3 hours at room temperature. The reaction mixture was poured into ice-water, and then was extracted with ethyl acetate. The extract was washed with water and was dried with anhydrous magnesium sulfate, and then this was evaporated in vacuo. The residue was purified with column chromatography with silica gel(Wako gel C-200 150g, elution with chloroform and then chloroform: methanol=99:1), resulting 1.3g of oily substance. This was dissolved in 10 ml of ethanol, 3 ml of 20% ethanol hydrochloride was added and evaporated in vacuo. Ether was added to the residue to crystallize. Whereby 1.32g of crystals were obtained. These were recrystallized with isopropanol, resulting to obtain 0.83g of crystals. Melting point is 165 to 167 °C.

Elementary analysis for (C ₁₉ H ₂₅ N ₃ O • 2HCl)			
Calculated (%)	C:57.00	H:6.80	N:10.50
Found (%)	C:57.28	H:6.94	N:10.31

In the same way as mentioned in practice example 1 to 5, the following compounds were prepared.

Example 6

4-[2-(N,N-diethylamino)ethoxy]-6-methyl-2-phenylpyrimidine dihydrochloride

Melting point 150-153 °C

Elementary analysis for (C ₁₇ H ₂₃ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:56.99	H:7.03	N:11.73
Found (%)	C:56.73	H:6.98	N:11.67

Example 7

4-[2-(N,N-dimethylamino)ethoxy]-6-methyl-2-phenylpyrimidine dihydrochloride

5 Melting point 184-186 °C

Elementary analysis for (C ₁₅ H ₁₅ N ₃ O • 2HCl)			
Calculated (%)	C:54.55	H:6.41	N:12.72
Found (%)	C:54.31	H:6.78	N:12.56

Example 8

15 4-Methyl-2-phenyl-6-(2-piperidinoethoxy) pyrimidine dihydrochloride

Melting point 179-181 °C

Elementary analysis for (C ₁₈ H ₂₃ N ₃ O • 2HCl)			
Calculated (%)	C:58.38	H:6.80	N:11.35
Found (%)	C:58.13	H:6.96	N:11.14

25 Example 9

4-Methyl-2-phenyl-6-(2-morpholinoethoxy)pyrimidine dihydrochloride

30 Melting point 181-182 °C

Elementary analysis for (C ₁₇ H ₂₁ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:54.85	H:6.23	N:11.29
Found (%)	C:54.61	H:6.48	N:11.46

Example 10

40 4-Methyl-2-phenyl-6-(3-piperidinopropoxy)pyrimidine dihydrochloride

Melting point 175-177 °C

Elementary analysis for (C ₁₉ H ₂₅ N ₃ O • 2HCl)			
Calculated (%)	C:59.38	H:7.08	N:10.98
Found (%)	C:59.29	H:7.23	N:10.97

Example 11

4-Methyl-2-phenyl-6-[2-(4-phenylpiperazino)ethoxy] pyrimidine maleate

5 Melting point 172-173 °C

10

Elementary analysis for (C ₂₃ H ₂₆ N ₄ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:66.11	H:6.16	N:11.42
Found (%)	C:66.33	H:6.01	N:11.53

Example 12

15

4-[2-[4-(4-methoxyphenyl)piperazino]ethoxy]-6-methyl-2-phenylpyrimidine maleate

Melting point 128-129 °C

20

Elementary analysis for (C ₂₄ H ₂₈ N ₄ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:64.60	H:6.20	N:10.76
Found (%)	C:64.70	H:6.19	N:10.75

25

Example 13

4-[2-(4-diphenylmethylpiperazino)ethoxy]-6-methyl-2-phenylpyrimidine

30 Melting point 113-115 °C

35

Elementary analysis for (C ₃₀ H ₃₂ N ₄ O)			
Calculated (%)	C:77.56	H:6.94	N:12.06
Found (%)	C:77.69	H:7.14	N:12.00

Example 14

40

4-[3-(4-diphenylmethylpiperazino)propoxy]-6-methyl-2-phenylpyrimidine dimaleate

Melting point 174-175 °C

45

Elementary analysis for (C ₃₁ H ₃₄ N ₄ O • 2C ₄ H ₄ O ₄)			
Calculated (%)	C:65.90	H:5.95	N:7.88
Found (%)	C:66.09	H:6.18	N:8.09

50

55

Example 15

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-methyl-2-phenylpyrimidine maleate

5 Melting point 176-177 °C

Elementary analysis for (C ₁₈ H ₂₁ N ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:64.22	H:6.12	N:10.21
Found (%)	C:64.36	H:6.17	N:10.08

Example 16

15 4-[2-(N,N-diethylamino)ethoxy]-2-(4-methoxyphenyl)-6-methylpyrimidine dihydrochloride

Melting point 182-184 °C

Elementary analysis for (C ₁₈ H ₂₅ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:55.67	H:7.01	N:10.82
Found (%)	C:55.83	H:7.04	N:10.90

Example 17

25 4-[2-(N,N-dimethylamino)ethoxy]-2-(4-methoxyphenyl)-6-methylpyrimidine dihydrochloride

30 Melting point 197-198 °C

Elementary analysis for (C ₁₆ H ₂₁ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:53.34	H:6.43	N:11.66
Found (%)	C:53.57	H:6.78	N:11.64

Example 18

40 2-(4-methoxyphenyl)-4-methyl-6-(2-piperidinoethoxy)pyrimidine dihydrochloride

Melting point 179-181 °C

Elementary analysis for (C ₁₉ H ₂₅ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:57.00	H:6.80	N:10.50
Found (%)	C:56.90	H:6.99	N:10.37

Example 19

2-(4-methoxyphenyl)-4-methyl-6-(2-morpholinoethoxy)pyrimidine dihydrochloride

5 Melting point 206-209 °C

10

Elementary analysis for (C ₁₈ H ₂₃ N ₃ O ₃ • 2HCl)			
Calculated (%)	C:53.74	H:6.26	N:10.44
Found (%)	C:53.72	H:6.41	N:10.47

Example 20

15

2-(4-methoxyphenyl)-4-methyl-6-(3-piperidinopropoxy)pyrimidine dihydrochloride

Melting point 187-188 °C

20

Elementary analysis for (C ₂₀ H ₂₇ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:57.97	H:7.05	N:10.14
Found (%)	C:57.88	H:7.19	N:10.08

25

Example 21

2-(4-methoxyphenyl)-4-methyl-6-[2-(4-phenylpiperazino) ethoxy]pyrimidine

30 Melting point 83-85 °C

35

Elementary analysis for (C ₂₄ H ₂₈ N ₄ O ₂)			
Calculated (%)	C:71.26	H:6.98	N:13.85
Found (%)	C:71.22	H:7.11	N:13.77

Example 22

40

2-(4-methoxyphenyl)-4-[2-[4-(4-methoxyphenyl)piperazino]ethoxy]-6-methylpyrimidine maleate

Melting point 149-150 °C

45

Elementary analysis for (C ₂₅ H ₃₀ N ₄ O ₃ • C ₄ H ₄ O ₄)			
Calculated (%)	C:63.26	H:6.22	N:10.18
Found (%)	C:63.36	H:6.17	N:10.15

50

55

Example 23

2-(4-methoxyphenyl)-4-methyl-6-[2-(4-phenylpiperidino)ethoxy]pyrimidine dihydrochloride

5 Melting point 151-155 °C

Elementary analysis for (C ₂₅ H ₂₉ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:63.02	H:6.56	N:8.82
Found (%)	C:62.86	H:6.37	N:8.98

Example 24

4-[2-[4-(4-chlorobenzoyl)piperazino]ethoxy]-2-(4-methoxyphenyl)-6-methylpyrimidine maleate

Melting point 164-165 °C

Elementary analysis for (C ₂₅ H ₂₇ ClN ₄ O ₃ • C ₄ H ₄ O ₄)			
Calculated (%)	C:59.74	H:5.36	N:9.61
Found (%)	C:59.40	H:5.46	N:9.59

Example 25

4-[2-[4-(4-methoxybenzoyl)piperazino]ethoxy]-2-(4-methoxyphenyl)-6-methylpyrimidine maleate

30 Melting point 156-157 °C

Elementary analysis for (C ₂₆ H ₃₀ N ₄ O ₄ • C ₄ H ₄ O ₄)			
Calculated (%)	C:62.27	H:5.92	N:9.68
Found (%)	C:62.11	H:6.14	N:9.67

Example 26

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-fluorophenyl)-6-methylpyrimidine maleate

Melting point 141.5-143 °C

Elementary analysis for (C ₁₈ H ₂₀ FN ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:61.52	H:5.63	N:9.78
Found (%)	C:61.74	H:5.92	N:9.71

Example 27

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-fluorophenyl)-6-methylpyrimidine maleate

5 Melting point 155.5-156.5 °C

10

Elementary analysis for (C ₁₈ H ₂₀ FN ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:61.52	H:5.63	N:9.78
Found (%)	C:61.30	H:5.92	N:9.81

Specific rotation [α]_D (20 °C) = -18.69 (c = 1, H₂O)

15

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-fluorophenyl)-6-methylpyrimidine hydrochloride

Melting point 277-278 °C

20

Elementary analysis for (C ₁₈ H ₂₀ FN ₃ O • HCl)			
Calculated (%)	C:61.80	H:6.05	N:12.01
Found (%)	C:61.57	H:5.95	N:12.08

Specific rotation [α]_D (20 °C) = -24.77 (c = 1, H₂O)

25

Example 28

(S)-(+)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-methoxyphenyl)-6-methylpyrimidine maleate

30 Melting point 159-161 °C

35

Elementary analysis for (C ₁₉ H ₂₃ N ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:62.57	H:6.16	N:9.52
Found (%)	C:62.30	H:6.34	N:9.71

Specific rotation [α]_D (20 °C) = +32.5 (c = 1, H₂O)

40 Example 29

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-chlorophenyl)-6-methylpyrimidine maleate

Melting point 161-162 °C

45

Elementary analysis for (C ₁₈ H ₂₀ ClN ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:59.26	H:5.43	N:9.42
Found (%)	C:59.30	H:5.38	N:9.37

50

55

Example 30

4-methylamino-6-methyl-2-phenylpyrimidine

5 Melting point 69-71 °C

Elementary analysis for (C ₁₂ H ₁₃ N ₃)			
Calculated (%)	C:72.33	H:6.57	N:21.09
Found (%)	C:72.36	H:6.69	N:21.14

Example 31

15 4-(N,N-diethylamino)-6-methyl-2-phenylpyrimidine hydrochloride

Melting point 161-163 °C

Elementary analysis for (C ₁₅ H ₁₉ N ₃ • HCl)			
Calculated (%)	C:64.85	H:7.26	N:15.13
Found (%)	C:64.69	H:7.43	N:15.37

Example 32

4-methyl-6-(2-morpholinoethylamino)-2-phenylpyrimidine dihydrochloride Melting point 251-253.5 °C

Elementary analysis for (C ₁₇ H ₂₂ N ₄ O • 2HCl)			
Calculated (%)	C:54.99	H:6.51	N:15.09
Found (%)	C:55.14	H:6.38	N:15.38

Example 33

40 4-[2-(N,N-diisopropylamino)ethylamino]-6-methyl-2-phenylpyrimidine dihydrochloride

Melting point 255-256 °C

Elementary analysis for (C ₁₉ H ₂₈ N ₄ • 2HCl)			
Calculated (%)	C:59.21	H:7.84	N:14.54
Found (%)	C:59.43	H:7.66	N:14.68

Example 34

4-methyl-6-(4-phenylpiperazino)-2-phenylpyrimidine

5 Melting point 95-97 °C

10

Elementary analysis for (C ₂₁ H ₂₂ N ₄)			
Calculated (%)	C:76.33	H:6.71	N:16.95
Found (%)	C:76.16	H:6.82	N:16.69

Example 35

15

4-(4-diphenylmethylpiperazino)-6-methyl-2-phenylpyrimidine

Melting point 201-203 °C

20

Elementary analysis for (C ₂₈ H ₂₈ N ₄)			
Calculated (%)	C:79.97	H:6.71	N:13.32
Found (%)	C:79.99	H:6.88	N:13.12

25

Example 36

4-amino-2-(4-methoxyphenyl)-6-methylpyrimidine

30 Melting point 177-180 °C

35

Elementary analysis for (C ₁₂ H ₁₃ N ₃ O)			
Calculated (%)	C:66.96	H:6.09	N:19.52
Found (%)	C:67.09	H:6.20	N:19.42

Example 37

40

2-(4-methoxyphenyl)-4-methyl-6-methylaminopyrimidine

Melting point 99-101 °C

45

Elementary analysis for (C ₁₃ H ₁₅ N ₃ O)			
calculated (%)	C:68.10	H:6.59	N:18.33
Found (%)	C:68.50	H:6.76	N:18.41

50

55

Example 38

2-(4-methoxyphenyl)-4-methyl-6-(2-morpholinoethylamino) pyrimidine

5 Melting point 144-146 °C

Elementary analysis for (C ₁₈ H ₂₄ N ₄ O ₂)			
Calculated (%)	C:65.83	H:7.37	N:17.06
Found (%)	C:65.69	H:7.45	N:16.82

Example 39

15 4-[2-(N,N-diethylamino)ethoxy]-2-methyl-6-phenylpyrimidine dihydrochloride

Melting point 195-197 °C

Elementary analysis for (C ₁₇ H ₂₃ N ₃ O • 2HCl)			
Calculated (%)	C:56.99	H:7.03	N:11.73
Found (%)	C:56.90	H:7.19	N:11.75

Example 40

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-methyl-6-phenylpyrimidine

30 Melting point 129-130 °C

Elementary analysis for (C ₃₀ H ₃₂ N ₄ O)			
Calculated (%)	C:77.56	H:6.94	N:12.06
Found (%)	C:77.38	H:7.15	N:11.92

Example 41

40 4-[2-(N,N-diethylamino)ethoxy]-6-(4-methoxyphenyl)-2-methylpyrimidine dihydrochloride

Melting point 168-171 °C

Elementary analysis for (C ₁₈ H ₂₅ N ₃ O ₂ • 2HCl)			
Calculated (%)	C:55.67	H:7.01	N:10.82
Found (%)	C:55.49	H:6.83	N:10.98

Example 42

4-[2-(4-diphenylmethylpiperazino)ethoxy]-6-(4-methoxyphenyl)-2-methylpyrimidine

5 Melting point 131-133 °C

10

Elementary analysis for (C ₃₁ H ₃₄ N ₄ O ₂)			
Calculated (%)	C:75.28	H:6.93	N:11.33
Found (%)	C:74.77	H:7.00	N:11.24

Example 43

15

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-(4-methoxyphenyl)-2-methylpyrimidine maleate

Melting point 145-147 °C

20

Elementary analysis for (C ₁₉ H ₂₃ N ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:62.57	H:6.16	N:9.52
Found (%)	C:62.30	H:6.34	N:9.62

25

Example 44

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-chlorophenyl)-6-methylpyrimidine maleate

30 Melting point 166-167 °C

35

Elementary analysis for (C ₁₈ H ₂₀ ClN ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:59.26	H:5.43	N:9.42
Found (%)	C:59.10	H:5.34	N:9.61

Specific rotation [α]_D (20 °C) = -35.03 (c = 1, H₂O)

40 Example 45

2-methyl-4-(2-morpholinoethylamino)-6-phenylpyrimidine dihydrochloride Melting point 277-282 °C

45

Elementary analysis for (C ₁₇ H ₂₂ N ₄ O)			
Calculated (%)	C:54.99	H:6.51	N:15.09
Found (%)	C:54.81	H:6.63	N:14.90

50

55

Example 46

4-(4-diphenylmethylpiperazino)-2-methyl-6-phenylpyrimidine

5 Melting point 195-198 °C

Elementary analysis for (C ₂₈ H ₂₈ N ₄)			
Calculated (%)	C:79.96	H:6.71	N:13.32
Found (%)	C:79.73	H:6.89	N:13.23

Example 47

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-chlorophenyl)-6-methylpyrimidine hydrochloride

Melting point 284-285.5 °C

Elementary analysis for (C ₁₈ H ₂₀ ClN ₃ O • HCl)			
Calculated (%)	C:59.02	H:5.78	N:11.47
Found (%)	C:58.79	H:5.66	N:11.51

25 Specific rotation [α]_D (20 °C) = -21.47 (c = 1, H₂O)

Example 48

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-methoxyphenyl)-6-trifluoromethylpyrimidine maleate

30 Melting point 173-174.5 °C

Elementary analysis for (C ₂₃ H ₂₄ F ₃ N ₃ O ₆)			
Calculated (%)	C:55.76	H:4.88	N:8.48
Found (%)	C:55.83	H:5.07	N:8.55

Example 49

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-methyl-2-(4-trifluoromethylphenyl)pyrimidine maleate

Melting point 173.5-174.5 °C

Elementary analysis for (C ₂₃ H ₂₄ F ₃ N ₃ O ₅)			
Calculated (%)	C:57.62	H:5.05	N:8.76
Found (%)	C:58.00	H:5.14	N:8.90

Example 50

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-trifluoromethylphenyl)-6-trifluoromethylpyrimidine maleate

5 Melting point 171-172 °C

10

Elementary analysis for (C ₁₉ H ₁₇ F ₆ N ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:51.79	H:3.97	N:7.88
Found (%)	C:51.88	H:4.03	N:7.93

Example 51

15

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-fluorophenyl)-6-trifluoromethylpyrimidine maleate

Melting point 176-177.5 °C

20

Elementary analysis for (C ₁₈ H ₁₇ F ₄ N ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:54.66	H:4.38	N:8.69
Found (%)	C:54.44	H:4.42	N:8.76

25

Example 52

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-(4-fluorophenyl)-6-methylpyrimidine

30 Melting point 120-121.5 °C

35

Elementary analysis for (C ₃₀ H ₃₁ FN ₄ O)			
Calculated (%)	C:74.66	H:6.47	N:11.61
Found (%)	C:74.58	H:6.62	N:11.51

Example 53

40

4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-2-(4-methoxyphenyl)-6-methylpyrimidine

Melting point 125-126 °C

45

Elementary analysis for (C ₃₁ H ₃₂ F ₂ N ₄ O ₂)			
Calculated (%)	C:70.17	H:6.08	N:10.56
Found (%)	C:70.11	H:6.06	N:10.55

50

55

Example 54

4-[2-(4-diphenylmethylpiperazino)ethoxy]-6-methyl-2-(4-trifluoromethylphenyl)pyrimidine

5 Melting point 161.5-162.5 °C

Elementary analysis for (C ₃₁ H ₃₁ F ₃ N ₄ O)			
Calculated (%)	C:69.91	H:5.87	N:10.52
Found (%)	C:69.51	H:5.82	N:10.51

Example 55

15 4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-6-methyl-2-(4-trifluoromethylphenyl)pyrimidine

Melting point 104.5-106 °C

Elementary analysis for (C ₃₁ H ₂₉ F ₅ N ₄ O)			
Calculated (%)	C:65.49	H:5.14	N:9.85
Found (%)	C:65.53	H:5.16	N:9.79

Example 56

4-[2-(4-diphenylmethylpiperazino)ethoxy]-2-(4-methoxyphenyl)-6-trifluoromethylpyrimidine

30 Melting point 117-118 °C

Elementary analysis for (C ₃₁ H ₃₁ F ₃ N ₄ O ₂)			
Calculated (%)	C:67.87	H:5.70	N:10.21
Found (%)	C:67.51	H:5.65	N:10.29

Example 57

40 4-[2-[4-[bis(4-fluorophenyl)methyl]piperazino]ethoxy]-2-(4-methoxyphenyl)-6-trifluoromethylpyrimidine

Melting point 104-106 °C

Elementary analysis for (C ₃₁ H ₂₉ F ₅ N ₄ O ₂)			
Calculated (%)	C:63.69	H:5.00	N:9.58
Found (%)	C:63.31	H:5.15	N:9.36

Example 58

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-hydroxyphenyl)-6-methylpyrimidine maleate

5 Melting point 177-179 °C

10

Elementary analysis for (C ₁₈ H ₂₁ N ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:61.82	H:5.89	N:9.83
Found (%)	C:61.50	H:5.90	N:9.82

Specific rotation [α]_D (20 °C) = -35.77 (c = 1, H₂O)

15

Example 59

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-tert-butyl-2-(4-methoxyphenyl)pyrimidine maleate

Melting point 198-199 °C

20

Elementary analysis for (C ₂₂ H ₂₉ N ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:64.58	H:6.88	N:8.69
Found (%)	C:64.77	H:6.81	N:8.73

25

Example 60

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-tert-butyl-2-(4-methoxyphenyl)pyrimidine maleate

30

Melting point 203-204 °C

35

Elementary analysis for (C ₂₂ H ₂₉ N ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:64.58	H:6.88	N:8.69
Found (%)	C:64.61	H:6.93	N:8.63

Specific rotation [α]_D (20 °C) = -41.26 (c = 1, CH₃OH)

40

Example 61

4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-tert-butyl-2-(4-fluorophenyl)pyrimidine maleate

45

Melting point 186-187 °C

50

Elementary analysis for (C ₂₁ H ₂₆ FN ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:63.68	H:6.41	N:8.91
Found (%)	C:63.68	H:6.42	N:8.85

55

Example 62

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-6-tert-butyl-2-(4-fluorophenyl)pyrimidine maleate

5 Melting point 203-205 °C

Elementary analysis for (C ₂₁ H ₂₆ FN ₃ O ₂ • C ₄ H ₄ O ₄)			
Calculated (%)	C:63.68	H:6.41	N:8.91
Found (%)	C:63.62	H:6.42	N:8.87

Specific rotation [α]_D (20 °C) = -30.63 (c = 1, CH₃OH)

15 Example 63

(R)-(-)-4-(1-azabicyclo[2,2,2]octo-3-yloxy)-2-(4-fluorophenyl)-6-trifluoromethylpyrimidine maleate

Melting point 172-173.5 °C

Elementary analysis for (C ₁₈ H ₁₇ F ₄ N ₃ O • C ₄ H ₄ O ₄)			
Calculated (%)	C:54.66	H:4.38	N:8.69
Found (%)	C:54.43	H:4.38	N:8.78

Specific rotation [α]_D (20 °C) = -41.54 (c = 1, CH₃OH)

Example 64

30 4-[2-[4-bis(4-fluorophenyl)methyl]piperazino]ethoxy]-2-(4-fluorophenyl)-6-methylpyrimidine trihydrochloride

Melting point 176-177 °C

Elementary analysis for (C ₃₀ H ₂₉ F ₃ N ₄ O • 3HCl)			
Calculated (%)	C:57.38	H:5.14	N:8.92
Found (%)	C:57.16	H:5.38	N:8.73

40 Test Examples

Results of pharmacological tests showing the usefulness of representative compounds of the present invention are given.

45 Methods

(1) Improvement effects on deficits of learning and memory induced by scopolamine.

50 A test drug suspended in 0.5 % methyl cellulose (MC) solution was administered orally to ten rats in a group. 30 minutes after this treatment, scopolamine at a dose of 0.3 mg/kg was given intraperitoneally to the animals. 30 minutes after the treatment of scopolamine, training trials of the step-through type passive avoidance task were carried out. 24 hours after the trial, test trials were carried out.

The step-through latency time in the test trial of rats was measured for up to 300 sec. The results were regarded as learning scores. (Table 1). The statistical significance compared with the control groups was analyzed using Kruskal-Wallis's test and Fisher's test. MC solution was given to the control groups.

Table 1. Improving effects on deficits of learning and memory (rats)

Drugs (Example NO.)	Dose p.o.	Latency (sec.)	
1	0.03	170.80 ±	44.15
	0.1	228.20 ±	37.47 **
	0.3	247.30 ±	35.16 **
	1	242.90 ±	38.07 **
	3	255.30 ±	30.85 **
	10	253.50 ±	31.18 **
	30	182.40 ±	40.25
MC	-	98.80 ±	43.95
2	0.01	161.30 ±	46.33
	0.03	231.40 ±	35.92 *
	0.1	253.10 ±	31.62 **
	0.3	271.00 ±	29.00 **
	1	245.40 ±	36.48 **
	3	249.60 ±	33.86 **
	10	192.60 ±	43.89
MC	-	90.20 ±	35.71
3	0.3	191.50 ±	44.37
	1	239.90 ±	31.58 *
	3	244.20 ±	37.21 **
	10	276.70 ±	23.30 **
	30	272.10 ±	27.90 **
MC	-	109.40 ±	41.87
4	1	143.90 ±	43.53
	3	204.50 ±	40.47
	10	245.70 ±	36.29 **
	30	279.20 ±	20.80 **

	MC	-	106.80 ± 42.66
5	6	0.1	179.80 ± 36.66
		0.3	200.40 ± 41.39 *
		1	222.80 ± 40.06 *
		3	223.50 ± 39.45 *
10		10	188.10 ± 40.24
	MC	-	99.90 ± 43.83
	11	1	212.70 ± 44.45
15		3	274.00 ± 26.00 **
		10	248.40 ± 34.40 **
		30	222.40 ± 39.90 *
		100	208.50 ± 38.37
20	MC	-	133.00 ± 43.62
	13	0.3	131.10 ± 46.13
		1	186.10 ± 46.51
25		3	286.50 ± 13.50 **
		10	245.70 ± 36.20 *
		30	242.60 ± 38.27 *
		100	169.20 ± 44.09
30	MC	-	105.50 ± 42.59
	15	1	270.50 ± 29.50 *
	MC	-	129.00 ± 46.60
35	21	1	170.00 ± 44.05
		3	243.50 ± 37.67 *
		10	272.70 ± 27.30 **
		30	276.90 ± 23.10 **
40	MC	-	132.00 ± 45.90
	23	0.3	156.40 ± 47.90
		1	243.10 ± 37.93 *
45		3	270.90 ± 29.10 **
		10	274.00 ± 26.00 **
		30	272.00 ± 28.00 **
50	MC	-	104.40 ± 42.79

26	0.03	217.80 ±	41.86
	0.1	249.30 ±	33.84 *
	0.3	271.00 ±	29.00 **
	1	274.50 ±	25.50 **
	3	273.10 ±	26.90 **
	10	271.50 ±	28.50 **
	30	185.70 ±	46.69 **
<hr/>			
MC	-	135.50 ±	44.95
27	0.01	214.90 ±	43.34
	0.03	247.80 ±	34.80 *
	0.1	272.90 ±	27.10 **
	0.3	271.60 ±	28.40 **
	1	274.00 ±	26.00 **
	3	272.90 ±	27.10 **
	10	167.70 ±	44.20
<hr/>			
MC	-	133.80 ±	45.31
35	0.1	153.10 ±	41.22
	0.3	162.40 ±	40.34
	1	253.30 ±	31.14
	3	274.90 ±	25.10 *
	10	173.20 ±	42.51
<hr/>			
MC	-	166.80 ±	44.59
44	0.03	196.80 ±	42.16
	0.1	272.00 ±	28.00 **
	0.3	271.40 ±	28.60 **
	1	273.30 ±	26.70 **
	3	271.00 ±	29.00 **
	10	246.60 ±	35.63 *
	30	196.70 ±	42.51
<hr/>			
MC	-	129.80 ±	46.35
58	0.01	215.90 ±	42.89
	0.03	252.00 ±	32.42 *
	0.1	274.20 ±	25.80 **
	0.3	272.50 ±	27.50 **
	1	272.80 ±	27.20 **
	3	187.10 ±	46.11
<hr/>			
MC	-	132.10 ±	45.74

MC: 0.5 % methyl cellulose

* $p < 0.05$

** $p < 0.01$

5

(2) Binding affinities for muscarinic receptors

10 The binding assay for muscarinic receptors was carried out according to the method of Yamamura and Snyder [Yamamura, H.I. and Snyder, S.H. ; Muscarinic cholinergic binding in rat brain. Proc.Natl.Acad.Sci. U.S.A.71:1725-1729 (1974)]. Namely the receptor membrane preparations from rat brain were incubated with 0.1 nM [3 H]quinuclidinyl benzilate (QNB) in 50mM Na/K phosphate buffer solution (pH 7.4) at 25 °C for 60 minutes. The strength of the binding affinity for muscarinic receptors was indicated as the concentration of drug required to displace 50 % of the [3 H]QNB binding (IC_{50}). The results are shown in Table 2.

15

Table 2

20

Binding affinities for muscarinic receptors	
Drugs (Example NO.)	IC_{50} (M)
1	7.8×10^{-6}
2	3.5×10^{-6}
15	3.3×10^{-6}
25 26	2.9×10^{-6}
27	1.6×10^{-6}
29	1.6×10^{-6}
44	1.4×10^{-6}
51	2.7×10^{-6}
30 58	9.9×10^{-6}
59	7.2×10^{-6}
61	5.8×10^{-6}
62	7.4×10^{-6}
35 63	3.7×10^{-6}
carbachol	1.0×10^{-4}
pilocarpine	8.3×10^{-6}

40 The compounds of the present invention exhibited equivalent or superior binding affinities for the central muscarinic receptors compared with pilocarpine or carbachol.

(3) Effect on muscarinic M_1 receptors

45 Binding assay for muscarinic M_1 receptors was carried out according to the method of Watson and Yamamura [Life Sci. 32 ; 3001-3011(1983)]. Namely, the receptor membrane preparations from rat brain were incubated with 1 nM [3 H]pirenzepine in 10 mM Na/K phosphate buffer solution (pH 7.4) at 25 °C for 60 minutes. 1 μ M of atropine was used as a displacer. The degree of binding affinities for muscarinic M_1 receptors were shown in table 3 as the concentration of drug which was required to displace 50 % of the [3 H]pirenzepine binding(IC_{50}).

50

55

Table 3

Effects on muscarinic M ₁ receptors	
Drugs (Example NO.)	IC ₅₀ (M)
2	6.5 x 10 ⁻⁷
27	1.7 x 10 ⁻⁷
44	2.4 x 10 ⁻⁷
58	8.1 x 10 ⁻⁷
60	3.1 x 10 ⁻⁶
62	2.8 x 10 ⁻⁶
63	6.0 x 10 ⁻⁷
carbachol	1.2 x 10 ⁻⁵

As shown in table 3, the compounds of the present invention exhibited inhibitory effects on the binding of [³H]pirenzepine to M₁ receptors. These effects were 10 to 100 times more potent than that of carbachol.

(4) Acute toxicity

Male mice, 6 weeks of age (4 mice/group) were deprived of foods overnight. Test drugs suspended in 0.5 % methyl cellulose solution were administered orally to the mice. Whether the animals were dead or not was observed 72 hours after the treatment of the drugs. The results were shown in table 4.

Table 4

Acute toxicity (mice, p.o.)		
Drugs (Example NO.)	Dose (mg/kg)	Lethality
3	1000	0/4
4	1000	0/4
11	1000	0/4
13	1000	0/4
21	1000	0/4
35	1000	0/4
44	1000	0/4
58	1000	0/4
(Number of dead animals/Number of animals used)		

It is clear from the table 4 that no death was observed when all of the compounds of the present invention administered to the animals at a dose of 1000 mg/kg. Pharmaceutical examples

Pharmaceutical preparations using the compounds of the present invention are as follows.

Pharmaceutical example 1 Injection

The injection in which the following prescription contained in 1ml of an ampule was prepared according to the usual method.

Prescription	The compound of Example 2 sodium chloride water for injection	1 mg 9 mg q.s.
--------------	---	----------------------

Pharmaceutical example 2 Injection

The injection in which the following prescription contained in 1ml of an ampule was prepared according to the usual method.

Prescription	The compound of Example 27 sodium chloride water for injection	1 mg 9 mg q.s.
--------------	--	----------------------

Pharmaceutical example 3 Injection

The injection in which the following prescription contained in 1ml of an ampule was prepared according to the usual method.

Prescription	The compound of Example 44 sodium chloride water for injection	1 mg 9 mg q.s.
--------------	--	----------------------

Pharmaceutical example 4 Injection

The injection in which the following prescription contained in 1ml of an ampule was prepared according to the usual method.

Prescription	The compound of Example 58 sodium chloride water for injection	1 mg 9 mg q.s.
--------------	--	----------------------

Pharmaceutical example 5 Oral liquid preparation

The oral liquid in which the following prescription contained in 100 ml was prepared according to the usual method.

Prescription	The compound of Example 2 simple syrup	20 mg q.s.
--------------	---	---------------

Pharmaceutical example 6 Oral liquid preparation

The oral liquid in which the following prescription contained in 100 ml was prepared according to the usual method

Prescription	The compound of Example 27 simple syrup	20 mg q.s.
--------------	--	---------------

Pharmaceutical example 7 Oral liquid preparation

The oral liquid in which the following prescription contained in 100 ml was prepared according to the usual method

Prescription	The compound of Example 44 simple syrup	20 mg q.s.
--------------	--	---------------

5

Pharmaceutical example 8 Oral liquid preparation

The oral liquid in which the following prescription contained in 100 ml was prepared according to the usual method

10

Prescription	The compound of Example 58 simple syrup	20 mg q.s.
--------------	--	---------------

15

Pharmaceutical example 9 Solid formulation

The tablet in which the following prescription contained in 120 mg of one tablet was prepared according to the usual method.

20

Prescription	The compound of Example 2	1 mg
	lactose	60 mg
	cornstarch	30 mg
	crystalline cellulose	20 mg
	hydroxypropylcellulose	7 mg
	magnesium stearate	2 mg

25

30 Pharmaceutical example 10 Solid formulation

The tablet in which the following prescription contained in 120 mg of one tablet was prepared according to the usual method.

35

Prescription	The compound of Example 27	1 mg
	lactose	60 mg
	cornstarch	30 mg
	crystalline cellulose	20 mg
	hydroxypropylcellulose	7 mg
	magnesium stearate	2 mg

40

Pharmaceutical example 11 Solid formulation

45

The tablet in which the following prescription contained in 120 mg of one tablet was prepared according to the usual method.

50

Prescription	The compound of Example 44	1 mg
	lactose	60 mg
	cornstarch	30 mg
	crystalline cellulose	20 mg
	hydroxypropylcellulose	7 mg
	magnesium stearate	2 mg

55

Pharmaceutical example 12 Solid formulation

The tablet in which the following prescription contained in 120 mg of one tablet was prepared according to the usual method.

Prescription	The compound of Example 58	1 mg
	lactose	60 mg
	cornstarch	30 mg
	crystalline cellulose	20 mg
	hydroxypropylcellulose	7 mg
	magnesium stearate	2 mg

15 Pharmaceutical example 13 Solid formulation

The powder in which the following prescription contained in 1 g was prepared according to the usual method.

Prescription	The compound of Example 2	2 mg
	lactose	996 mg
	Aerosil	2 mg

25 Pharmaceutical example 14 Solid formulation

The powder in which the following prescription contained in 1 g was prepared according to the usual method.

Prescription	The compound of Example 27	2 mg
	lactose	996 mg
	Aerosil	2 mg

35 Pharmaceutical example 15 Solid formulation

The powder in which the following prescription contained in 1 g was prepared according to the usual method.

Prescription	The compound of Example 44	2 mg
	lactose	996 mg
	Aerosil	2 mg

45 Pharmaceutical example 16 Solid formulation

The powder in which the following prescription contained in 1 g was prepared according to the usual method.

Prescription	The compound of Example 58	2 mg
	lactose	996 mg
	Aerosil	2 mg

Pharmaceutical example 17 Suppository

The suppository in which the following prescription contained in 2g of one suppository was prepared according to the usual method.

Prescription	The compound of Example 2 suppository base	2 mg q.s.
--------------	---	--------------

Pharmaceutical example 18 Suppository

The suppository in which the following prescription contained in 2g of one suppository was prepared according to the usual method.

Prescription	The compound of Example 27 suppository base	2 mg q.s.
--------------	--	--------------

Pharmaceutical example 19 Suppository

The suppository in which the following prescription contained in 2g of one suppository was prepared according to the usual method.

Prescription	The compound of Example 44 suppository base	2 mg q.s.
--------------	--	--------------

Pharmaceutical example 20 Suppository

The suppository in which the following prescription contained in 2g of one suppository was prepared according to the usual method.

Prescription	The compound of Example 58 suppository base	2 mg q.s.
--------------	--	--------------


EFFECTS OF THE INVENTION

The compounds of the present invention are useful as reactivators of acetylcholinergic nervous system since they show eminent improvement effects on learning and memory disorders as well as have potent binding affinities for muscarinic receptors. Also, their safety margins are very wide.


The compounds of the present invention have superior effects that is not demonstrated in other known drugs, and also those have wider safety margins. Therefore those can be used as therapeutic drugs for senile dementia or as well as dementia and the like disease accompanied by mental-growth retardation, sequelae of encephalitis, cerebral palsy, cerebral apoplexy, cerebral arteriosclerosis, head injury and so forth.

Claims


1. Pyrimidine derivatives and their pharmacologically acceptable salts represented by the following general formula [I]




10 wherein A and B are as follows:
When A represents



20 B represents methyl, trifluoromethyl, or tert-butyl;
when B represents




30 A represents methyl, trifluoromethyl, or tert-butyl.
Wherein R¹ and R² are the same or different and each is a hydrogen atom, a hydroxy group, an alkoxy group, trifluoromethyl or halogen.
R³ represents (1), (2) or (3), represented by the following formulas.



40 wherein Y represents O or NH.




50 wherein R⁴ and R⁵ represent the following ① or ②.
①. R⁴ and R⁵ are the same or different and each is hydrogen or alkyl group.
②. R⁴ and R⁵ link to form piperazino which is substituted with an aryl group or an aralkyl group.




wherein Y represents O or NH. m is 2 or 3. R⁶ and R⁷ are the same or different and each is a hydrogen atom or an alkyl group, or form a 5 to 6 membered cyclic-amino group with the adjacent nitrogen atom. These cyclic-amino groups may include another nitrogen, oxygen or sulfur atom, and moreover, those may be substituted with an aryl group with or without substituent(s), an aralkyl group with or without substituent(s), or an aroyl group with or without substituent(s).

However the following compounds (i)-(x) are excluded.


(i) The compound wherein A is phenyl, B is methyl and R³ is




(ii) The compound wherein A is phenyl, B is methyl and R³ is




(iii) The compound wherein A is methyl, B is phenyl and R³ is



(iv) The compounds wherein A is methyl, B is phenyl and R³ is



(v) The compound wherein A is methyl, B is phenyl and R³ is



(vi) The compound wherein A is methyl, B is phenyl and R³ is -NH₂.


(vii) The compound wherein A is methyl, B is 4-chlorophenyl and R³ is -NH₂.

(viii) The compound wherein A is methyl, B is 4-methoxyphenyl and R³ is -NH₂.

(ix) The compound wherein A is phenyl, B is methyl and R³ is -NH₂.

(x) The compound wherein A is 4-chlorophenyl, B is methyl and R³ is -NH₂.


2. An agent of improving learning or memory disorders comprising a pyrimidine derivative represented by the following general formula [I] or their pharmacologically acceptable salt as an active ingredient.



10 wherein A and B are as follows:
When A represents



20 B represents methyl, trifluoromethyl, or tert-butyl when B represents




A represents methyl, trifluoromethyl, or tert-butyl.

30 Wherein R¹ and R² are the same or different and each is a hydrogen atom, a hydroxy group, an alkoxy group, trifluoromethyl or halogen.


R³ represents (1), (2) or (3), represented by the following formulas.

35 (1)



40 wherein Y represents O or NH.

(2)




50 wherein R⁴ and R⁵ represent the following ① or ②.

①. R⁴ and R⁵ are the same or different and each is hydrogen or an alkyl group.

②. R⁴ and R⁵ link to form piperazino which is substituted with an aryl group or an aralkyl group.

55 (3)



wherein Y represents O or NH. m is 2 or 3. R⁶ and R⁷ are the same or different and each is a hydrogen atom or an alkyl group, or form a 5 to 6 membered cyclic-amino group with the adjacent nitrogen atom. These cyclic-amino groups may include another nitrogen, oxygen or sulfur atom, and moreover, those may be substituted with an aryl group with or without substituent(s), an aralkyl group with or without substituent(s), or an aroyl group with or without substituent(s).

5

10

15

20

25

30

35

40

45

50

55

INTERNATIONAL SEARCH REPORT

International Application No PCT/JP91/01152

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int. Cl ⁵ C07D239/34, 239/42, 453/02, A61K31/505		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
IPC	C07D239/34, 239/42, 453/02, A61K31/505	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
X	JP, B1, 40-15197 (Rikagaku Kenkyusho), July 16, 1965 (16. 07. 65), (Family: none)	1
X	JP, B1, 48-21949 (Farbwerke Hoechst AG.), July 2, 1973 (02. 07. 73), & US, A, 3787411	1, 2
X	JP, A, 61-44872 (Fujisawa Pharmaceutical Co., Ltd.), March 4, 1986 (04. 03. 86) & US, A, 4725600 & EP, A, 168262	1, 2
<p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
November 14, 1991 (14. 11. 91)	December 2, 1991 (02. 12. 91)	
International Searching Authority	Signature of Authorized Officer	
Japanese Patent Office		